Bipartisan No More: Top Dems Denounce Draft Biomedical Reform Legislation
Executive Summary
Reps. Diana DeGette and Frank Pallone expressed disappointment with House Energy and Commerce 21st Century Cures bill; meanwhile Senate Republicans kick off their own reform process.
You may also be interested in...
21st Century Cures Bill Could Create More Prescriptive Rx Approval Standards For FDA
Simplified and speedier drug approval process is focus for Reps. Upton and DeGette’s upcoming legislation – but getting there may mean more congressional micromanaging over FDA’s drug approval standards.
Congress Dives Into Biomedical Innovation: Will It Drown In A Deep Sea Of Competing Needs?
House Energy and Commerce committee says it’s committed to a bill to accelerate U.S. biomedical innovation before the next FDA user fee cycle, but the wide scope of needs and stakeholders may make crafting legislation challenging – never mind getting it passed.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.